Methods of using low molecular weight heparins treatment of pathological processes
US5474987A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 3, 1995 |
| Grant date | Dec 12, 1995 |
| Priority date | — |
| Expiry date | Feb 3, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods for the prevention and/or treatment of pathological processes involving the induction of TNF-.alpha. secretion comprising a pharmaceutically acceptable carrier and a low molecular weight heparin (LMWH). In the pharmaceutical compositions of the present invention, the LMWH is present in a low effective dose and is administered at intervals of about 5-8 days. Furthermore, the LMWH is capable of inhibiting in vitro TNF-.alpha. secretion by resting T cells and/or macrophages in response to T cell-specific antigens, mitogens, macrophage activators, disrupted extracellular matrix (dECM), laminin, fibronectin, and the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.